Oyunbileg Magvanjav, MD, PhD
Clinical FellowAbout
Research
Publications
2025
Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Magvanjav O, Bergwitz C. Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease. JCEM Case Reports 2025, 3: luaf031. PMID: 40110572, PMCID: PMC11920620, DOI: 10.1210/jcemcr/luaf031.Peer-Reviewed Original ResearchGiant cell tumor of boneBone-specific alkaline phosphataseGiant cell tumorOne-time doseTumor of boneCell tumorsPaget's diseaseCalcitriol-mediated hypercalcemiaOsteoclast-like giant cellsDose of denosumabTreated with bisphosphonatesReduced tumor sizeElevated calcitriolParathyroid autonomyPolyostotic PDBStromal mononuclear cellsPelvic massSymptomatic hypercalcemiaTumor regrowthTumor sizeParathyroid hormoneKidney injuryNormal calciumMononuclear cellsDenosumab
2024
5150 When Few Options Exist: Graves’ Disease Treated With Potassium Iodide And Levothyroxine Block-And-Replace Therapy
Magvanjav O, Majumdar S. 5150 When Few Options Exist: Graves’ Disease Treated With Potassium Iodide And Levothyroxine Block-And-Replace Therapy. Journal Of The Endocrine Society 2024, 8: bvae163.2127. PMCID: PMC11454244, DOI: 10.1210/jendso/bvae163.2127.Peer-Reviewed Original ResearchGraves' diseaseLiver enzyme levelsHepatic function panelsTreatment optionsNormalization of thyroid hormonesBlood pressureEffective first-line agentThyroid hormonesTreatment of Graves' diseaseElevated liver enzyme levelsElevated free T4Radioactive iodine therapyFirst-line agentsLimited treatment optionsHistory of palpitationsBaseline neutrophil countUnintentional weight lossThyroid hormone levelsElevated blood pressureEnzyme levelsWeeks of initiationTreated with KIMetoprolol XLFunction panelDefinitive therapy5150 When Few Options Exist: Graves’ Disease Treated with Potassium Iodide and Levothyroxine Block-and-Replace Therapy
Magvanjav O, Majumdar S. 5150 When Few Options Exist: Graves’ Disease Treated with Potassium Iodide and Levothyroxine Block-and-Replace Therapy. Journal Of The Endocrine Society 2024, 8: bvae163.2211. PMCID: PMC11455131, DOI: 10.1210/jendso/bvae163.2211.Peer-Reviewed Original ResearchGraves' diseaseLiver enzyme levelsHepatic function panelsTreatment optionsNormalization of thyroid hormonesBlood pressureEffective first-line agentThyroid hormonesTreatment of Graves' diseaseElevated liver enzyme levelsElevated free T4Radioactive iodine therapyFirst-line agentsLimited treatment optionsHistory of palpitationsBaseline neutrophil countUnintentional weight lossThyroid hormone levelsElevated blood pressureEnzyme levelsWeeks of initiationTreated with KIMetoprolol XLFunction panelDefinitive therapy
2023
THU667 Severe Hypothyroidism With Paradoxically Elevated Direct Free T4 Due To Anti-thyroxine Antibodies
Magvanjav O, McPhaul M, Choucair I, Holt E. THU667 Severe Hypothyroidism With Paradoxically Elevated Direct Free T4 Due To Anti-thyroxine Antibodies. Journal Of The Endocrine Society 2023, 7: bvad114.1790. PMCID: PMC10554396, DOI: 10.1210/jendso/bvad114.1790.Peer-Reviewed Original ResearchThyroid-stimulating hormoneThyroid function testsNon-pitting edemaElevated thyroid-stimulating hormoneFT4 levelsLaboratory interferenceClinical symptomsAbnormal thyroid function testsThyroid-stimulating hormone levelsFunction testsNormal body mass indexDry skinElevated FT4 levelsElevated TSH levelsThyroid hormone levelsBody mass indexElevated blood pressureLevothyroxine doseNormal heart rateHypothyroid patientsTSH levelsSevere hypothyroidismThyroid disordersBilateral shinsFree T4
2019
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting
Magvanjav O, Cooper-Dehoff R, McDonough C, Gong Y, Hogan W, Johnson J. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. American Journal Of Hypertension 2019, 33: 316-324. PMID: 31853537, PMCID: PMC7109351, DOI: 10.1093/ajh/hpz196.Peer-Reviewed Original ResearchConceptsElectronic health recordsDrug class combinationsBP controlElectronic health record dataClinical decision supportDrug classesEvidence of associationHistory of myocardial infarctionImprove BP controlHealthcare ImprovementConcomitant diseasesUncomplicated hypertensionHealth recordsMyocardial infarctionBlood pressureManagement of hypertensionDual antihypertensive therapyPrescribing practicesReal-world settingsPrescribingAntihypertensive drug classesBlood pressure controlPrescribing patternsAmbulatory hypertensive patientsPrescribed frequency
2018
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease
Magvanjav O, Cooper‐DeHoff R, McDonough C, Gong Y, Segal M, Hogan W, Johnson J. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. Journal Of Clinical Hypertension 2018, 21: 91-101. PMID: 30427124, PMCID: PMC6329007, DOI: 10.1111/jch.13429.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlack or African AmericanBlood PressureCase-Control StudiesComorbidityDiureticsDrug CombinationsFemaleHumansHypertensionHypertension, MalignantMaleMiddle AgedProteinuriaRenal Insufficiency, ChronicRisk FactorsUnited StatesConceptsChronic kidney disease patientsAngiotensin-converting enzyme inhibitorsChronic kidney diseaseAngiotensin receptor blockersResistant hypertensionAntihypertensive therapyBeta-blockersAntihypertensive drug prescribing patternsKidney diseaseBlood pressureRisk factorsRisk of resistant hypertensionElectronic health recordsDrug prescribing patternsStage-specific treatmentBlood pressure controlAfrican American raceReceptor blockersHypertensive patientsRenoprotective agentPrescribing patternsControlled BPAmerican racePatientsEnzyme inhibitorsGenetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses)
McDonough C, Magvanjav O, Sá A, El Rouby N, Dave C, Deitchman A, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh R, Solayman M, Bailey K, Boerwinkle E, Chapman A, Gums J, Webb A, Scherer S, Sadee W, Turner S, Cooper-DeHoff R, Gong Y, Johnson J. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circulation Genomic And Precision Medicine 2018, 11: e001854. PMID: 29650764, PMCID: PMC5901893, DOI: 10.1161/circgen.117.001854.Peer-Reviewed Original ResearchConceptsSingle-nucleotide polymorphismsBaseline plasma renin activityGenome-wide association studiesPEAR studyPlasma renin activityFunctional evidenceRNA sequencing dataPEAR-2BP response to atenololSequence dataAssociation studiesGene regionDirection of associationGenetic variantsG alleleGene expressionRenin activityBlood pressureMultiple linear regression analysisResponse prioritizationLinear regression analysisResponse to antihypertensive agentsResponse to atenololResponse to hydrochlorothiazideGenes
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials
Magvanjav O, Gong Y, McDonough C, Chapman A, Turner S, Gums J, Bailey K, Boerwinkle E, Beitelshees A, Tanaka T, Kubo M, Pepine C, Cooper‐DeHoff R, Johnson J. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials. Journal Of The American Heart Association 2017, 6: e006522. PMID: 29097388, PMCID: PMC5721751, DOI: 10.1161/jaha.117.006522.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic beta-AntagonistsAdultAgedAldehyde Dehydrogenase 1 FamilyAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtenololBlood PressureCalcium Channel BlockersChi-Square DistributionDrug CombinationsDrug ResistanceFemaleFloridaGenome-Wide Association StudyGeorgiaHumansHydrochlorothiazideHypertensionIndolesLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPharmacogeneticsPharmacogenomic VariantsPolymorphism, Single NucleotideProspective StudiesRetinal DehydrogenaseRisk FactorsSodium Chloride Symporter InhibitorsTreatment OutcomeVasodilator AgentsVerapamilYoung AdultConceptsGenome-wide association studiesGenome-wide significanceCombination therapyUncontrolled BPSingle nucleotide polymorphismsBlood pressureVariant associationsNucleotide polymorphismsGenetic variantsAssociated with uncontrolled BPMultivariate logistic regression analysisCombination antihypertensive therapyAdequate blood pressureDiastolic BP responseGenesReplication cohortUncontrolled blood pressureLogistic regression analysisMajor alleleAntihypertensive therapyB-blockersPolymorphismReplicationExternal cohortBP responseMultisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D, Kimmel S, McDonough C, Gong Y, Dave C, Pratt V, Alestock T, Anderson R, Alsip J, Ardati A, Brott B, Brown L, Chumnumwat S, Clare-Salzler M, Coons J, Denny J, Dillon C, Elsey A, Hamadeh I, Harada S, Hillegass W, Hines L, Horenstein R, Howell L, Jeng L, Kelemen M, Lee Y, Magvanjav O, Montasser M, Nelson D, Nutescu E, Nwaba D, Pakyz R, Palmer K, Peterson J, Pollin T, Quinn A, Robinson S, Schub J, Skaar T, Smith D, Sriramoju V, Starostik P, Stys T, Stevenson J, Varunok N, Vesely M, Wake D, Weck K, Weitzel K, Wilke R, Willig J, Zhao R, Kreutz R, Stouffer G, Empey P, Limdi N, Shuldiner A, Winterstein A, Johnson J, Network I. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovascular Interventions 2017, 11: 181-191. PMID: 29102571, PMCID: PMC5775044, DOI: 10.1016/j.jcin.2017.07.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedClinical Decision-MakingClopidogrelCytochrome P-450 CYP2C19Drug ResistanceFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPharmacogeneticsPharmacogenomic TestingPharmacogenomic VariantsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePredictive Value of TestsRisk AssessmentRisk FactorsTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsGenotype-guided antiplatelet therapyCYP2C19 genotype-guided antiplatelet therapyCYP2C19 loss-of-function allelesLoss-of-function allele carriersPercutaneous coronary interventionAdverse cardiovascular eventsAntiplatelet therapyCardiovascular eventsAlternative therapiesRandomized studyLoss-of-function allelesAllele carriersCoronary interventionClinical implementationMonths of percutaneous coronary interventionInverse probability of treatment weightingInverse probabilityPercutaneous coronary intervention patientsProbability of treatment weightingAcute coronary syndromeAlternative antiplatelet therapyClopidogrel effectCoronary syndromeCox regressionClinical genotypingPharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)
Magvanjav O, McDonough C, Gong Y, McClure L, Talbert R, Horenstein R, Shuldiner A, Benavente O, Mitchell B, Johnson J. Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke 2017, 48: 1337-1343. PMID: 28351962, PMCID: PMC5404951, DOI: 10.1161/strokeaha.116.015936.Peer-Reviewed Original ResearchConceptsArterial ischemic strokeAssociated with MACESPS3 trialPharmacogenetic associationsB-blockersIschemic strokeHistory of strokeMultivariate Cox regression analysisB-blocker treatmentCox regression analysisAll-cause deathIschemic stroke patientsComponents of MACEStroke patientsGly49 carriersSer49Ser genotypeAfrican ancestryGly49 alleleCarrier statusArg389Gly polymorphismReceptor polymorphismsPolymorphismGenetic substudyKaplan-MeierCardiovascular outcomes
News & Links
News
Get In Touch
Events
Mar 20266Friday
Everyone Oyunbileg Magvanjav, MD, PhD